Skip to main content
logo
Call
Menu

Detect beta-amyloid (Aβ) levels with a simple blood test that's less invasive and more affordable than traditional methods—giving your patients increased accessibility to testing they need.

 

Identify and monitor beta-amyloid levels associated with increased AD risk years before observable symptoms appear and often long before plaque build up becomes visible on imaging.

Plan your approach to care, inclusive of further diagnostic testing, lifestyle changes, or therapies that may help slow disease progression.

Accessibility for you and your patients. 

Blood-based biomarker tests offer unparalleled accessibility and convenience, enabling a broader population to access early diagnosis and monitoring for AD. Quest is one of the largest national labs with a network of approximately 2,100 Patient Service Center locations. That means your patients can get their blood drawn where it's convenient for them, ultimately streamlining the diagnostic process. AD-Detect Amyloid Beta 42/40 Ratio can pave the way to help determine if more extensive testing—like CSF or PET—is necessary.

 

7in10

Establish a baseline and monitor your patients throughout their journey.

Identify AD risk early and continually monitor your patient's amyloid beta biomarkers over time. Our enhanced reporting provides Aβ42/40 ratio values from current and 5 past results all in one table.

Detect early pathological changes of AD within plasma

The accessibility and cost-effectiveness of plasma biomarker tests like Quest AD-Detect® Amyloid Beta Ratio plays a critical role in the diagnostic process of AD. In a published study, plasma Aβ42/Aβ40 ratio was significantly correlated with Aβ-PET levels.2

Paving the way for timely interventions.

Quest AD-Detect® Amyloid Beta 42/40 Ratio paves the way for early disease detection and timely interventions. Evaluating these blood biomarker levels can guide care decisions including lifestyle changes and treatments that may delay or mitigate disease progression.3

Quest AD-Detect Amyloid Beta 42/40 Test Details

   

The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease 

Hear experts discuss the current opportunities and challenges in diagnosing AD, the emerging role, of blood­based biomarkers (e.g., P-tau, Aβ42/Aβ40, Nfl) in screening and monitoring, and exploring new treatments and diagnostics pathways to help inform patient care. 

 

Watch the webinar

See how we are actively working to empower you with insights to drive care for patients with dementia 

View full portfolio

REFERENCES 

1. Alzheimer’s Association. 2023 Alzheimer’s disease facts and figures. Accessed October 3, 2023. https://alz.org/media/Documents/alzheimers-facts-and-figures-infographic.pdf

2. Pascual-Lucas M, Allué JA, Sarasa L, et al. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline. Alzheimer’s Research & Therapy. 2023;15(1). doi:https://doi.org/10.1186/s13195-022-01143-z

3. Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. Alzheimer's Dement (NY). 2021; 7(1):e12179. doi:1 0.1 002/trc2.12179. 

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.